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A double-blind placebo-controlled trial of intravenous 
prostaglandin PGE, (40 pg/h) was conducted in adult 
orthotopic liver transplant recipients. Infusion was 
started intraoperatively and continued for up to 21 days. 
Patients were followed up for 180 days postoperatively. 
Among 172 patients eligible for treatment in the study, 
160 could be evaluated (78 PGE1; 82 placebo). Patient 
and graft survival were similar (PGE,: 16 deaths, 9 re- 
transplantations 17 survivors]; controls: 15 deaths, 6 re- 
transplantations [3 survivorsl). In patients with swlriv- 
ing grafts, however, PGE, administration resulted in a 
23% shorter mean duration of hospitalization following 
transplantation (PGE,: 24.4 days; controls: 31.8 days; P 
= .02) and a 40% shorter length of time postoperatively 
in the intensive care unit (PGE1: 8.2 days; controls 13.7 
days; P = .05). Reduced needs for renal support (P = .03) 
or surgical intervention other than retransplantation (P 
= .02) were also noted with PGE, use. Further, PGEl 
administration resulted in a trend toward improved sur- 
vival rates in patients with mild renal impairment (pre- 
operative serum creatinine 1.5 mg percent or greater; P 
= .08). Neither the incidence of acute cellular rejection 
nor of primary nonfunction was significantly different 
in the two groups. Phlebitis was the only complication 
that was more common during PGE, administration, 
(PGE,: 9; controls: 4). These results suggest that PGEl 
use in hepatic allograft recipients reduces morbidity 
and may result in sizable cost reductions. (HEPATOLOGY 
1995;21:366-372.) 
Abbreviation: PGE, prostaglandin El.  
From the Departments of Internal Medicine, Division of Gastroenterology, 
Anesthesiology, Surgery, and Pathology, the University of Michigan Medical 
School; and the School of Public Health, Division of Biostatistics, the Univer- 
sity of Michigan, Ann Arbor, MI. 
Received March 8, 1994; accepted August 16, 1994. 
Supported in part by the General Clinical Research Center (MOI-RR00042 
of the NIH). 
Dr Mackie is now a t  Middlemure Hospital, Aukland, New Zealand, and Dr 
Ham is now at the Department of Surgery, Medical College of Virginia, Rich- 
mond, VA. 
Address reprint requests to: Keith S. Henley, MU, Department of Internal 
Medicine, Division of Gastroenterology, 3912 Taubman Center, University of 
Michigan Medical Center, Ann Arbor, MI 48109-0362. 
Copyright 8 1995 by the American Association for the Study of Liver 
Diseases. 
0270-9139/95/2102-0015$3.00/0 
Despite advances in surgical technique, donor-organ 
preservation, and immediate and long-term allograft 
management, orthotopic liver transplantation remains 
fraught with immunologic, physiologic, hemodynamic, 
and microbiologic problems. Consequently, liver trans- 
plantation continues to  have a high early morbidity 
and mortality.' Early graft failure frequently leads to  
retransplantation, which depletes the scarce donor-or- 
gan pool and increases costs. Furthermore, early mor- 
tality and lengthy hospitalization for postoperative 
morbidity are associated with the highest charges for 
orthotopic liver transplantation.' 
Prostaglandins of the E family have properties sug- 
gestive of a potential to  improve liver allograft function. 
A range of inhibitory actions on the cellular immune 
responses that may characterize acute rejection has 
been shown with exogenous prostaglandin E (PGE). In 
uitro studies have documented PGE inhibition of mu- 
rine lymphocyte-mediated cytotoxicity" and splenic T- 
cell-mediated toxicity against target hepat~cytes,~ as 
well as inhibition of human lymphocyte interleukin-2- 
driven alloproliferative re~ponses .~ In uiuo investiga- 
tions have shown PGE suppression of acute immune- 
complex-induced vasculitis and adjuvant-induced 
polyarthritis in rats6 and of the immune response in a 
model of systemic lupus erythematosus in mice.7 
PGE also has been shown to have an impact on non- 
immune actions that may have effects on liver allo- 
grafts. Investigations have documented in uitro 
changes in human erythrocyte membrane flexibility,' 
increases in canine hepatic blood flow,' and changes in 
the ratio of insulin and glucagon in human serum." 
More specifically, collagen formation has been shown 
to be delayed by 16,16-dimethyl PGE, in rodent models 
of hepatic injury from a fibrogenic and by a 
PGE, analogue in rats that had undergone bile duct 
1igati0n.l~ 
Furthermore, 16,16-dimethyl PGE, has been shown 
to increase survival by decreasing the level of circulat- 
ing tumor necrosis factor in rats following endotoxin 
~ha1lenge.l~ PGE analogues also have been shown to 
protect liver in situ and hepatocytes in culture15 from 
damage by murine hepatitis virus type 3 and to inhibit 
hepatic-reperfusion injury or free-radical-mediated 
liver damage in animal transplantation  model^.'^,'^ 
Data from clinical trials suggest that exogenous pros- 
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taglandins may be beneficial in solid-organ trans- 
plantations. In a double-blind, placebo-controlled study 
of oral PGEl in renal-transplant recipients, acute graft 
refection occurred less frequently in the PGE-treated 
group (P  = .02).l8 A subsequent study of PGEz in renal 
transplantation, however, did not confirm these obser- 
vations." In human liver transplantation, a nonran- 
domized, controlled study showed a reduced number of 
early liver allograft rejection episodes in PGE,-treated 
patients (P  = .003) in the first 6 weeks following pri- 
mary orthotopic liver transplantation.zo In other stud- 
ies, PGEl has been reported to improve 1iver,21-23 re- 
nal,24z25 and platelet? function and possibly to  
ameliorate primary nonfunction after orthotopic liver 
tran~plantation. '~ 
Despite these encouraging data, rigorous controlled 
clinical trials of prostaglandin agonists in the early 
postoperative management of orthotopic liver grafts 
are lacking. We, therefore, initiated a double-blind, 
randomized, placebo-controlled trial of intravenous 
PGE in adult orthotopic liver-transplant recipients. 
MATERIALS AND METHODS 
Patients and Study Design. Between April 20, 1990 and 
November 3, 1992, all patients aged 18 years or older who 
were on the liver-transplantation waiting list a t  the Univer- 
sity of Michigan Medical Center were invited to participate. 
Patients who may have previously been enrolled in the study 
and who were waiting for retransplantation also were eligible 
if the first transplantation had been performed a t  least 180 
days earlier. This allowed ample time for the effects of PGEi, 
which the patient may have received earlier to dissipate. The 
study was approved by the institutional review board of the 
University of Michigan. Informed consent was requested 
from all eligible patients and was obtained from all those 
who enrolled. Immediately before transplantation, patients 
were assigned to receive either PGEl or placebo infusion un- 
der a randomization code generated by the University of 
Michigan School of Public Health and kept by the Division of 
Investigational Pharmacy, University of Michigan Hospitals. 
PGE, (Prostin VR Pediatric) was provided by the Upjohn 
Company, Kalamazoo, Mich. The infusion was started at a 
rate of 10 p g h  before the anhepatic phase and was increased 
by 10 p g h  every 30 minutes until a maintenance level of 40 
p g h  had been reached. When the infusion contained PGEl, 
this protocol ensured that the newly transplanted organ 
would be exposed to the drug as  soon as the clamps were 
released. A fresh infusion was prepared every 24 hours, and 
infusions were continued for up to 21 days. Infusion was 
stopped for the following reasons: discharge from the hospi- 
tal, treatment failure caused by primary nonfunction, miscel- 
laneous adverse events, retransplantation, or death. When 
primary nonfunction occurred, the blind code was maintained 
although the patient may have been switched to open-label 
PGE, infusion. As a precaution, a physician who was not an 
investigator under this protocol had access to this randomiza- 
tion code. When 20 patients had been enrolled, and again 
about midway through the study, he examined the mortality 
data to determine whether to continue the study. 
Normal posttransplantation care routine was maintained 
during this study. The immunosuppressive regimen included 
administration of methylprednisolone (initially 200 mg/d and 
then progressively lower doses), azathioprine 1 mgkg/d, and 
antilymphocyte globulin (20 mgkg for a t  least 5 days), and 
cyclosporin A, once renal function had become normal or had 
stabilized. Cyclosporine was given a t  an initial oral dose of 
14 mgkg/d. When a therapeutic level (150 -t 25 pg/mL whole 
blood as measured by high-performance liquid chromatogra- 
phy) had been reached, the antilymphocyte globulin was dis- 
continued. Protocol liver biopsies were performed a t  7, 14, 
and 21 days and additionally as clinically indicated. 
Definition of Endpoints. Mortality was defined as death 
from any cause within 180 days of the transplantation. Mor- 
bidity was defined on the basis of time spent in the hospital 
during the first 180 days after transplantation, time spent 
in the intensive care unit with or without ventilatory support, 
and the duration of the initial hospitalization following trans- 
plantation. 
Complications were categorized as the initiation of artifi- 
cial renal support (dialysis or continuous arterio-venous he- 
mofiltration), reoperations, reintubation, gastrointestinal 
bleeding, or major infections. Reoperation was classified as 
surgical intervention for therapeutic purposes (excluding en- 
doscopic or biopsy procedures, paracentesis, thoracentesis, or 
the insertion of monitoring equipment). Major infections were 
defined as isolation of one or more recognized pathogens from 
blood, serous cavities, or sputum (if accompanied by an infil- 
trate on chest radiograph), andor isolation of fungal organ- 
isms from any source other than skin, urine, or catheter tip. 
Gastrointestinal bleeding was defined as bleeding from the 
gastrointestinal tract requiring transfusion. 
Because the benefit of shortened hospital stay cannot be 
applied to  patients who die or require retransplantation, 
these patients were excluded from analyses of morbidity data 
as defined above. 
Primary nonfunction of the allograft was diagnosed if a 
patient met at least five of the following criteria: bile output 
of <20 mL in 24 hours; serum bilirubin greater than 10 mg% 
and increasing a t  a rate of a t  least 5 mgo/r/d; prothrombin 
time of 15 seconds or longer; factor V concentration 525% 
of normal levels; patency of major vessels demonstrated by 
Doppler ultrasound; and a clinical picture compatible with 
primary nonfunction. 
The diagnosis of acute cellular rejection was based on the 
histopathologic criteria of Snover et  aLZ7 Chronic ductopenic 
rejection was based on the histopathologic criteria of Ludwig 
et  aLZs 
Statistical Methods. To determine, prospectively, the num- 
ber of patients required to complete the study, it was postu- 
lated that the incidence of acute cellular rejection would need 
to be lowered from 33%, which was the incidence in our pro- 
gram when the trial was begun, to about 16% and that the 
duration of hospitalization should be reduced by one third. 
With a significance level of 5% and a power of 8 O % ,  the calcu- 
lated sample size was 85 patients in each group. 
Data were extracted from patients' charts, entered into 
text files by a professional data-entry firm, and then trans- 
ferred to a statistical data base. All statistical analyses were 
performed using SAS software (Statistical Analysis System, 
Cary, NC). 
Comparisons of nominal variables between treatment 
groups were made by Fisher's exact test.gg The differences in 
lengths of various stays (e.g., days in the intensive care unit 
between treatment groups were evaluated by the Wilcoxon's 
rank-sum test.3" All significance values reported are based 
on two-tailed tests. 
RESULTS 
Among 172 patients considered for enrollment in the 
protocol, 2 patients were found to be ineligible because 
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TABLE 1. Treatment Group Assignment and Mortality 
Among Patients Who Were Rerandomized and 
Retransplanted During the Study and Who Were Excluded 
From Analyses 
Treatment Group No. of Survivors 
Assignments No. of Patients of Retransplantation 
PGE, then PGE, 2 2 
PGE, then placebo 1 0 
Placebo then PGE, 4 3 
Placebo then placebo 2 1 
of incorrect documentation of the informed consent, 
and 5 refused randomization. An additional 9 patients 
were excluded from analyses because they underwent 
retransplantation and were rerandomized, and re- 
treated within 180 days. The outcomes of the retrans- 
plantation operations in these 9 rerandomized patients 
are shown in TabIe 1. Four patients underwent retrans- 
plantation and were rerandomized into the study after 
completing 180 days of follow-up; these patients were 
included as 8 patients in the analyses. The study was 
terminated and the code was broken on May 11, 1993, 
after the last enrolled patient had completed 180 days 
of follow-up. 
Among 160 patients analyzed, PGE, was adminis- 
tered to 78 patients, and placebo was given to 82 pa- 
tients. The clinical characteristics of these 160 patients 
are shown in Table 2, and the outcomes of the trans- 
plantation operation after 180 days of follow-up are 
shown in Table 3. Also, the distribution of known pre- 
dictors of outcome, such as age or transplantation from 
the intensive care unit or preoperative renal status (Ta- 
ble 2), did not differ significantly between the two 
groups. There was no difference in mortality or in the 
frequency of retransplantation within 180 days be- 
tween the two groups. The causes of death among those 
TABLE 2. Characteristics of Patients Who Completed 180 
Days of Follow-Up After Liver Transplantation 
Characteristic PGE, Placebo 
(N = 78) (N = 82) 
Mean age in years -t SEM 
Sex MIF 41/37 40142 
Transplanted from ICU 12 14 
Diagnosis 
Alcohol-induced cirrhosis 32 27 
Cryptogenic cirrhosis 9 15 
Primary biliary cirrhosis 8 8 
43.6 2 1.34 44.9 2 1.42 
Hepatitis C 5 7 
Primary sclerosing cholangitis 5 4 
Chronic hepatitis B 2 1 
Chronic autoimmune hepatitis 2 5 
Fulminant hepatitis 3 3 
Chronic hepatitis (B + C) 1 1 
Wilson’s disease 1 2 
Others 10 9 
TABLE 3. Mortality and Retransplantation Within 180 Days 
Following Liver Transplantation in PGE, and Placebo 
Treatment Groups 
Retransplantation 




Alive 53 58 
Dead 16 15 
Alive 7 6 
Dead 2 3 
Alive 59 64 
Dead 18 18 
patients who did not undergo retransplantation within 
180 days are listed in Table 4. 
Nine patients experienced primary graft nonfunction 
and were then administered open-label PGEl infusions 
(three patients in the PGEl group and six control pa- 
tients: Table 5). An additional three patients (two PGEI 
patients and one control patient) were withdrawn from 
the protocol (i.e., infusion was halted) by the attending 
surgeon without their meeting all the criteria for pri- 
mary nonfunction. 
Hospitalization data (Table 6) for the patients with 
surviving grafts showed that, in comparison with con- 
trols, PGE1-treated patients spent 40% fewer days in 
the intensive care unit (P = .05) and 23% less time in 
the hospital during the transplant admission (P  = .02). 
In addition, the mean number of total days of hospital- 
ization during the first 180 days after surgery was less 
by 22% for the PGE-treated group than for controls, 
although the difference between the groups did not 
achieve significance ( P  = .lo). 
Analyses of the incidence of major complications indi- 
cated that, in comparison with control patients, sig- 
nificantly fewer PGEl-treated patients required renal 
support (P = .03) or reoperation (P = .02) (Table 7). 
Although reintubations were more frequent among pa- 
tients in the placebo group than in patients who re- 
TABLE 4. Causes of Death Among Patients not Receiving 
Retransplants Within 180 Days Following 
Liver Transplantation 
No. of Deaths 
Cause Of Death 
PGEl Placebo 































Total 16 15 
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TABLE 5. Outcome in Nine Patients With Primary 
Nonfunction During Infusion With PGE, (Three Patients) 
or Placebo (Six Patients) 






* This patient was in the PGE,-treated group. 
ceived PGE1, the difference between groups was not 
significant ( P  = .08). The incidences of gastrointestinal 
bleeding and infections were similar in the two groups. 
The distribution of the indications for reoperation in 
the PGE,-treated group and in the control group is pre- 
sented in Table 8. 
Although mortality among patients with renal fail- 
ure (serum creatinine 21.5 mg%) a t  the time of trans- 
plantation was lower in patients treated with PGEl 
than in control patients, the difference between the 
groups was not significant (P = .08) (Table 9). 
Liver biopsy showed evidence of acute cellular rejec- 
tion in 17 of 64 PGE,-treated patients (26%) and in 28 
of 74 placebo-treated patients (38%; P = .20). In some 
instances, death or clinical contraindication precluded 
the performance liver biopsies. During the period of 
PGEl infusion, acute cellular rejection was diagnosed 
in 1 patient, and incomplete evidence of rejection (all 
but one of the criteria for rejection present) was seen 
in 3 other patients. 
Chronic ductopenic rejection was diagnosed in three 
patients treated with PGEl, two of whom showed acute 
cellular rejection on an earlier biopsy, and in five pla- 
cebo-treated patients, three of whom showed acute cel- 
lular rejection on an earlier biopsy. 
Events that led to  discontinuation of infusion before 
21 days are listed in Table 10. These patients received 
the drug for a mean of 12.6 ? 0.94 (SEM) days. None 
of the adverse events were severe. Hypotension, gastro- 
intestinal symptoms, and headache did not occur. 
Computerized laboratory data were available on all 
but the first 24 patients. These are summarized in Ta- 
TABLE 6. Morbidity in Terms of Time Spent in the Hospital 
During the Study by Patients Who Completed 
180 Days of Follow-Up 
Mean No. of Days 
(SEMI 
PGE, Placebo 
Time Period (N = 53) (N = 58) PValue 
In intensive care unit 8.2 (1.3) 13.7 (3.1) .05 
In hospital during transplantation 
admission 24.4 (3.01) 31.8 (3.9) .02 
In hospital during first 180 
postoperative days 32.5 (3.3) 41.5 (4.2) .10 
TABLE 7. Incidence of Major Complications, Excluding 
Patients Who Died or Who Underwent Retransplantation 
Placebo PGE, 
Complication (N = 53) (N = 58) P Value 
Renal support required 1 8 .03 
Reoperations required 
0 43 35 .02 
1 9 14 
2 2  1 9 
0 50 48 
21 1 2 
Reintubations .08 
Infections 8 11 .64 
Gastrointestinal bleeding 2 2 .61 
ble 11. The data were similar except for a statistical 
difference in the serum bilirubin. 
One patient deserves comment. This 39-year-old 
man was identified in the course of review of the intra- 
operative records to determine the possible mechanism 
of the PGE effect. He was randomized to receive the 
drug, and the infusion was prepared and provided by 
the pharmacy. As he developed hypotension, sufficient 
to  require dopamine, during the induction of anesthe- 
sia and before the incision was made, it was elected by 
the anesthesiologist to remove him from the study. He 
therefore did not receive PGE, at  any time. He survived 
after 31 days of intubation, 48 days in the intensive 
TABLE 8. Indications for Reoperations in PGEl and Placebo 
Treatment Groups (Excluding Deaths and Retransplants)* 
PGE, Placebo 

































































*: Patients may have required more than one reoperation. 
t Includes one patient requiring a tracheotomy at  operation. 
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TABLE 9. Mortality During 180 Days Following 
Transplantation in Patients With Preoperative Serum 
Creatinine Levels of 1.5 mg%o or Greater in PGE, and 
Placebo Treatment Groups 







care unit, 103 days during the initial hospitalization 
and four subsequent admissions, so that he spent 142 
of the first 180 days after surgery in the hospital. His 
course was characterized by three laparotomies, in- 
cluding one in which a tracheotomy was performed. His 
preoperative creatinine level was 2.5 mg%. He required 
artificial renal support on two separate occasions dur- 
ing his initial admission for 28 and 29 days, respec- 
tively, and had two separate episodes of infection. His 
liver biopsy specimens did not show conclusive evi- 
dence of rejection. Although this patient contributed 
significantly to the postoperative morbidity of the pa- 
tients assigned to receive active drug, it was elected to 
retain him in the study under the intent-to-treat rule. 
DISCUSSION 
This study reports the mortality and morbidity pro- 
file of perioperative PGE, infusion in orthotopic liver 
transplantation. Although neither an effect on mortal- 
ity nor on the need for retransplantation was shown, 
other evidence of significant clinical benefit was ob- 
tained. Comparisons with placebo infusion showed that 
PGE, administration resulted in decreased morbidity 
as evidenced by a 23% shorter initial hospital stay and 
a reduction of 40% in time spent in the intensive care 
unit. Although a detailed economic analysis is being 
conducted separately, the present data suggest that 
PGE, administered early in the operative course may 
significantly reduce the cost of liver transplantation. 
In comparison with control patients, the shorter 
length of initial hospitalization in PGE,-treated pa- 
tients may be attributed to the decreased need for post- 
operative renal support, the lowered incidence of rein- 
tubation, and a nonspecific trend toward a reduced 
need for reoperations over a broad spectrum of indica- 
tions. In addition, PGE, did not increase the incidence 
of infections or hemorrhagic complications, and the an- 
ticipated gastrointestinal symptoms were not seen. 
Our data also suggest that patients with high preop- 
erative serum creatinine concentrations (2  1.5 mg%) 
are more likely to survive liver transplantation when 
given PGE, . Previous studies have shown that such 
patients carry a greater risk of postoperative mortal- 
The mechanisms by which PGE, exerts its effects are 
not clear. The main benefit of the drug may possibly 
be based on a hemodynamic, hematologic, or cardiovas- 
cular effect rather than on direct action on the allograft. 
In the present study, PGE, had ample time to  equili- 
brate between the circulation and body tissues other 
itY.31232 
than liver before the transplanted organ was placed in 
circulation. Indeed, use of preservation solution con- 
taining prostaglandin for liver preperfusion immedi- 
ately before release of the clamps may merit evaluation 
because the fate of the transplanted liver may be deter- 
mined within seconds of renewed circulation. 
Alternatively, PGE, may exert its effect via modula- 
tion of the immune response because prostaglandins 
are immunosuppressive mediators."3 In vitro studies in 
rats indicate that during sepsis prostaglandins may 
down-regulate the release and consequently the circu- 
lating levels of specific ~ y t o k i n e s . ~ ~  A preliminary sur- 
vey of tumor necrosis factor, interleukin-8, interleukin- 
6, and monocyte chemotactic peptide in the present 
study population, however, did not suggest that the 
concentrations in serum of these cytokines were modi- 
fied by PGE, infusion (Kimberly A. Brown, unpub- 
lished data). 
The effects of PGEl on the liver were not striking. 
In particular, PGE, did not significantly decrease the 
incidence of acute cellular rejection. Acute cellular re- 
jection occurred not only after the PGE, infusion had 
been stopped but even during its administration. 
Based on the work of Greig et al,23 we had hoped 
that the PGE,-treated patients would be spared the 
complication of primary graft nonfunction. We found, 
however, that PGEl did not have significant effect on 
the incidence of this complication or its outcome. Pri- 
mary graft nonfunction should be diagnosed by a clus- 
ter of clinical and biochemical parameters that may 
reflect hemodynamic, immunologic, hematologic, and 
possibly other factors that have not been measured and 
that may obscure a heterogeneous etiology. 
Our earlier studies35 suggested that biochemical de- 
terminations on the transplanted liver are not very 
sensitive indicators of histopathological changes. Like- 
wise, in this study there were no significant differences 
in AST, ALT, AP activities, and platelet concentrations 
at a time when PGEl was still being received. The dif- 
ferences in the serum bilirubin concentrations are in- 
teresting, but not of striking clinical significance, nor 
can they be interpreted without additional data. 
The lack of a clearly demonstrable effect of PGE, on 
TABLE 10. Adverse Events Resulting in Early 
Discontinuation of PGE, or Placebo Infusion 
No. of Patients 
Adverse Events PGE, Placebo 
Phlebitis 9 4 
No reason noted 
Joint pains 
Patient request 
Neurological problems, possibly PGE related 
Sepsis 
Physician judgment 
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TABLE 11. Laboratory Data Mean t 1 SEM (n) 
AP (IU) PLT X 1O1lrnm1 Bilirubin ( m e )  AST (IU) ALT (IU) 
Post-Op Day 2 
4.85 Z 0.56 1,088 t 178 990 t 162 96.8 t 8.4 68.1 t 6.0 
(71) (71) (71) (71) (69) 
Placebo 6.95 2 0.71 1,520 t 252 1,182 2 185 109 2 12.6 63 t 23 
PGE 1 
(73) (73) (73) (73) (73) 
P < ,025 
Post-Op Day 10 
(61) (61) (61) (61) (61) 
(67) (67) (67) (67) (67) 
PGEl 5.86 ? 0.76 106 t 19 286 t 48 187 t 13 131 t 13 
Placebo 9.49 ? 1.1 135 t 27 296 t 45 187 t 17 139 ? 16 
P < ,005 
the liver may be explained by the relatively low inci- 
dence of any complication involving the liver paren- 
chyma in this study. In contrast to our results, a recent 
study'" showed a significantly lower incidence of early 
rejection (within the first 6 weeks following liver trans- 
plantation) in patients receiving PGE, (55%) compared 
with patients receiving placebo (80%; P = .023). 
Further work is needed to determine the mecha- 
nism(s) of action of the drug in hepatic allograft recipi- 
ents and to  optimize its use. The latter may require 
modification of the immunosuppressive protocol, modi- 
fication of the dose, and/or administration of PGEl pre- 
operatively. In the present investigation, PGEl lowered 
the incidence of postoperative renal failure and reduced 
the likelihood that patients would need to return to the 
operating room. The observed favorable trends in the 
incidence of acute cellular rejection and in chronic duc- 
topenic rejection also favor the drug despite the lack of 
statistical significance in the present trial. Additional 
studies may further define the role of PGEl in the man- 
agement of hepatic allograft recipients. 
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